General Serum Diluent
General Serum Diluent is formulated for diluting goat, rabbit, mouse, avian, and human sera, as well as mouse ascites fluid and cell culture media, for testing in sandwich ELISA configurations. General Serum Diluent can also be used for dilution of many types of serum samples, including mammalian and chicken, tested in antigen-down ELISA formats.
General Serum Diluent
General Serum Diluent is formulated for diluting goat, rabbit, mouse, avian, and human sera, as well as mouse ascites fluid and cell culture media, for testing in sandwich ELISA configurations. This product can also be used for dilution of many types of serum samples, including mammalian and chicken, tested in antigen-down ELISA formats.
Hyper-immunized serum samples contain nonspecific IgG antibody that may interfere with the titration. Proprietary additives have been incorporated into the General Serum Diluent formulation to minimize nonspecific binding interactions of the nonspecific IgG in the samples, thus decreasing assay background noise. General Serum Diluent may also be used for dilutions of the antigen standard for use in antibody capture sandwich ELISA formats.
Bulk volumes and custom packaging are available upon request.
2-8°C
Domestic: Overnight Delivery; International: Priority Shipping
7.4 at 1X
1X
Mammalian Proteins
United States
Expires two years from date of manufacture
- Prepare standards and samples in General Serum Diluent.
- Serum samples should generally be diluted at least 1:50 in order to minimize backgrounds caused by non-specific antibody binding.
- To dilute the sample 1:100, add 1 part sample to 99 parts General Serum Diluent. For example, add 10 μL sample to 990 μL sample diluent for a total of 1,000 μL.
- Highly concentrated samples may need to be diluted 1:1,000 or more.
- Once diluted, run the assay according to the specific ELISA protocol.
Allen, D;Hanumantharao, SN;McDonell, R;Irvine, KA;Sahbaie, P;Clark, D;Blum, P. Preclinical characterization of the efficacy and safety of biologic N-001 as a novel pain analgesic for post-operative acute pain treatment. Scientific reports. 2023 July
Arakawa, N;Matsuyama, S;Matsuoka, M;Kitamura, I;Miyashita, K;Kitagawa, Y;Imai, K;Ogawa, K;Maeda, T;Saito, Y;Hasegawa, C. Serum stratifin and presepsin as candidate biomarkers for early detection of COVID-19 disease progression. Journal of Pharmacological Sciences. 2022 September 1; doi: 10.1016/j.jphs.2022.06.002. Text